277 related articles for article (PubMed ID: 16304269)
21. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Rapp RP
Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
[TBL] [Abstract][Full Text] [Related]
22. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
23. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
Querol-Ribelles JM; Tenías JM; Querol-Borrás JM; Labrador T; Nieto A; González-Granda D; Martínez I
Int J Antimicrob Agents; 2005 Jan; 25(1):75-83. PubMed ID: 15620830
[TBL] [Abstract][Full Text] [Related]
24. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia.
Rahav G; Fidel J; Gibor Y; Shapiro M
Int J Antimicrob Agents; 2004 Aug; 24(2):181-4. PubMed ID: 15288319
[TBL] [Abstract][Full Text] [Related]
25. [Antibiotic therapy of severe community-acquired pneumonia].
Molchanova OV; Suleĭmanov SSh; Ostrovskiĭ AB
Antibiot Khimioter; 2009; 54(3-4):29-31. PubMed ID: 19711847
[TBL] [Abstract][Full Text] [Related]
26. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia.
Rittenhouse BE; Stinnett AA; Dulisse B; Henke CJ; Potter L; Parasuraman B; Martens LL; Williams RR; Kojak C
Am J Manag Care; 2000 Mar; 6(3):381-9. PubMed ID: 10977438
[TBL] [Abstract][Full Text] [Related]
27. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Morganroth J; Dimarco JP; Anzueto A; Niederman MS; Choudhri S;
Chest; 2005 Nov; 128(5):3398-406. PubMed ID: 16304291
[TBL] [Abstract][Full Text] [Related]
28. High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study.
Lee JH; Kim SW; Kim JH; Ryu YJ; Chang JH
Clin Drug Investig; 2012 Sep; 32(9):569-76. PubMed ID: 22765645
[TBL] [Abstract][Full Text] [Related]
29. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.
Erard V; Lamy O; Bochud PY; Bille J; Cometta A; Calandra T
Eur J Clin Microbiol Infect Dis; 2004 Feb; 23(2):82-8. PubMed ID: 14727149
[TBL] [Abstract][Full Text] [Related]
30. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen.
Tribble DR; Sanders JW; Pang LW; Mason C; Pitarangsi C; Baqar S; Armstrong A; Hshieh P; Fox A; Maley EA; Lebron C; Faix DJ; Lawler JV; Nayak G; Lewis M; Bodhidatta L; Scott DA
Clin Infect Dis; 2007 Feb; 44(3):338-46. PubMed ID: 17205438
[TBL] [Abstract][Full Text] [Related]
31. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors.
Leroy O; Saux P; Bédos JP; Caulin E
Chest; 2005 Jul; 128(1):172-83. PubMed ID: 16002932
[TBL] [Abstract][Full Text] [Related]
32. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
[TBL] [Abstract][Full Text] [Related]
33. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy.
Romanelli G; Cravarezza P; Pozzi A; Franchino L; Ravizzola G; Zulli R; Donati P; Prometti P; Grassi V
J Chemother; 2002 Dec; 14(6):609-17. PubMed ID: 12583553
[TBL] [Abstract][Full Text] [Related]
34. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.
Lin TY; Lin SM; Chen HC; Wang CJ; Wang YM; Chang ML; Wang CH; Liu CY; Lin HC; Yu CT; Hsieh LL; Kuo HP; Huang CD
Chang Gung Med J; 2007; 30(4):321-32. PubMed ID: 17939262
[TBL] [Abstract][Full Text] [Related]
35. Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis.
Suzuki J; Sasabuchi Y; Hatakeyama S; Matsui H; Sasahara T; Morisawa Y; Yamada T; Yasunaga H
J Infect Chemother; 2019 Dec; 25(12):1012-1018. PubMed ID: 31227381
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
37. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
Griffin AT; Peyrani P; Wiemken T; Arnold F
Int J Tuberc Lung Dis; 2010 Apr; 14(4):495-9. PubMed ID: 20202309
[TBL] [Abstract][Full Text] [Related]
38. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
39. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the effectiveness and antibiotic cost among ceftriaxone, ertapenem, and levofloxacin in treatment of community-acquired complicated urinary tract infections.
Lin HA; Yang YS; Wang JX; Lin HC; Lin DY; Chiu CH; Yeh KM; Lin JC; Chang FY
J Microbiol Immunol Infect; 2016 Apr; 49(2):237-42. PubMed ID: 25661278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
